Mesoblast Limited – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Mesoblast Limited - Product Pipeline Review - 2012" provides data on the Mesoblast Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Mesoblast Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Mesoblast Limited and industry-specific third party sources, put together by our team.
Scope
- Mesoblast Limited - Brief Mesoblast Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mesoblast Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mesoblast Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mesoblast Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Mesoblast Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mesoblast Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mesoblast Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mesoblast Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mesoblast Limited and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Mesoblast Limited Snapshot
Mesoblast Limited Overview
Key Information
Key Facts
Mesoblast Limited – Research and Development Overview
Key Therapeutic Areas
Mesoblast Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Mesoblast Limited – Pipeline Products Glance
Mesoblast Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Mesoblast Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Mesoblast Limited – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Mesoblast Limited – Drug Profiles
Adult-derived Mesenchymal Precursor Cells for Diabetes
Product Description
Mechanism of Action
R&D Progress
bone marrow-derived allogeneic mesenchymal precursor cells
Product Description
Mechanism of Action
R&D Progress
Drug Targeting Plasminogen Activator Inhibitor Type 1
Product Description
Mechanism of Action
R&D Progress
Drug Targeting Stromal-Derived Factor 1
Product Description
Mechanism of Action
R&D Progress
NeoFuse
Product Description
Mechanism of Action
R&D Progress
RepliCart
Product Description
Mechanism of Action
R&D Progress
revascor
Product Description
Mechanism of Action
R&D Progress
Stem Cells For Chronic Back Pain
Product Description
Mechanism of Action
R&D Progress
Stem Cells For Diabetic Macular Edema
Product Description
Mechanism of Action
R&D Progress
Stem Cells For Macular Degeneration
Product Description
Mechanism of Action
R&D Progress
Mesoblast Limited – Pipeline Analysis
Mesoblast Limited – Pipeline Products by Therapeutic Class
Mesoblast Limited – Pipeline Products by Route of Administration
Mesoblast Limited – Pipeline Products By Mechanism of Action
Mesoblast Limited – Recent Pipeline Updates
Mesoblast Limited – Company Statement
Mesoblast Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Mesoblast Limited, Recent Developments
Mesoblast Limited- Press Release
Jul 24, 2012: Mesoblast Announces Positive Preclinical Results Of Intravenously Injected Adult Stem Cells For Treatment Of Rheumatoid Arthritis
Apr 17, 2012: Mesoblast Announces Intervertebral Disc Repair Phase II Trial Update
Jan 31, 2012: Mesoblast Receives FDA Clearance For Phase II Clinical Trial Of Stem Cell Therapy In Type 2 Diabetes
Nov 18, 2009: Heart failure clinical trial results highlighted at American Heart Association annual meeting
Aug 05, 2009: Proprietary Technology in World-first Allogeneic Stem Cell Trial for Treatment of End-stage Heart Failure in Patients Supported by Mechanical Heart Assist Devices
May 14, 2009: Heart Muscle Function Improved Significantly After Single, Lowest-dose Injection of "off-the-shelf" Stem Cells in Patients with Heart Failure
Feb 25, 2009: First Group of Heart Failure Patients Treated With "off-the-shelf" Adult Stem Cells Successfully Pass Key Safety Milestone
Jan 20, 2009:
Financial Deals Landscape
Mesoblast Limited, Deals Summary
Mesoblast Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Parkway Group Healthcare Enters Into Co-Marketing Agreement With Mesoblast
Angioblast Systems Enters Into A Co-Development Agreement With Abbott India
Licensing Agreements
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine
Equity Offering
Mesoblast Completes Private Placement Of $33 Million
Angioblast Systems Completes Private Placement Of Common Stock For $8 Million
Mesoblast Completes Private Placement Of $7.51 Million
Mesoblast Completes Private Placement For $12 Million
Mesoblast Completes Public Offering Of $1.6 Million
Mesoblast Completes Private Placement Of $11 Million
Acquisition
Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Mesoblast Completes Acquisition Of Additional Stake In Angioblast Systems
Mesoblast Acquires Additional Stake In Angioblast
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Mesoblast Limited, Key Information
Mesoblast Limited, Key Facts
Mesoblast Limited – Pipeline by Indication, 2012
Mesoblast Limited – Pipeline by Stage of Development, 2012
Mesoblast Limited – Monotherapy Products in Pipeline, 2012
Mesoblast Limited – Phase III, 2012
Mesoblast Limited – Phase II, 2012
Mesoblast Limited – Pre-Clinical, 2012
Mesoblast Limited – Pipeline By Therapeutic Class, 2012
Mesoblast Limited – Pipeline By Route of Administration, 2012
Mesoblast Limited – Pipeline Products By Mechanism of Action, 2012
Mesoblast Limited – Recent Pipeline Updates, 2012
Mesoblast Limited, Other Locations
Mesoblast Limited, Subsidiaries
Mesoblast Limited, Deals Summary
Parkway Group Healthcare Enters Into Co-Marketing Agreement With Mesoblast
Angioblast Systems Enters Into A Co-Development Agreement With Abbott India
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine
Mesoblast Completes Private Placement Of $33 Million
Angioblast Systems Completes Private Placement Of Common Stock For $8 Million
Mesoblast Completes Private Placement Of $7.51 Million
Mesoblast Completes Private Placement For $12 Million
Mesoblast Completes Public Offering Of $1.6 Million
Mesoblast Completes Private Placement Of $11 Million
Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Mesoblast Completes Acquisition Of Additional Stake In Angioblast Systems
Mesoblast Acquires Additional Stake In Angioblast
List of Figures
Mesoblast Limited – Pipeline by Indication, 2012
Mesoblast Limited – Pipeline by Stage of Development, 2012
Mesoblast Limited – Monotherapy Products in Pipeline, 2012
Mesoblast Limited – Pipeline By Therapeutic Class, 2012
Mesoblast Limited – Pipeline By Route of Administration, 2012 30
